FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) with its spinal cord stem cells.
[Read the full article here]Related News:
Stem cell therapy used to fight amyotrophic lateral sclerosis
Neuralstem Receives Approval To Commence First ALS Stem Cell Trial At Emory ALS Center
FDA Approves Continuation of Emory Spinal Cord Stem Cell Research Trials